rheumatology
Psoriatic arthritis

Tofacitinib improves dermatologic symptoms and QoL in PsA

The JAK inhibitor tofacitinib (Xeljanz) provides improvement in patient-reported dermatologic symptoms and quality of life sustained for up to a year in patients with psoriatic arthritis, a new study shows. An analysis of patient reported dermatologic endpoints from two PsA studies – OPAL Broaden and OPAL Beyond  – found that tofacitinib was more effective than ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic